AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26324322
Drug: Movement System
RxNorm normalized name: JOINT MOVEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Movement System Impairment (MSI) treatment
Trial: 22367794
Drug: Immunonutrition (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunonutrition (1000 ml/day for 5 days before surgery)
Trial: 18558642
Drug: Olanzapine plus
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine plus day hospital treatment
Trial: 18558642
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus day hospital treatment
Trial: 12480497
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human IL-2 at doses of 10,000 IU/kg bw
Trial: 12480497
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human IL-2 at doses of 1000 IU/kg bw
Trial: 10361648
Drug: Standard discharge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard discharge preparation (control)
Trial: 11509937
Drug: 250 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg/kg intravenous immunoglobulin
Trial: 11509937
Drug: 500 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/kg intravenous immunoglobulin
Trial: 22957483
Drug: tongue protector
RxNorm normalized name: beef tongue preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tongue protector and 0.5 ml AV at 70% three times a day
Trial: 22957483
Drug: tongue protector
RxNorm normalized name: beef tongue preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tongue protector and 0.5 ml placebo three times a day
Trial: 21226818
Drug: Dapagliflozin (2.5-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (2.5-50 mg in SAD study; 2.5-20 mg QD for 14 days in MAD study)
Trial: 29426388
Drug: Home-based occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based occupational therapy intervention
Trial: 23579002
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (SB) supplementation (0.3 g/kg body mass)
Trial: 23573950
Drug: Givinostat 50
RxNorm normalized name: givinostat
DrugBank: Givinostat (DB12645)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Givinostat 50 mg/d
Trial: 23573950
Drug: Givinostat 100
RxNorm normalized name: givinostat
DrugBank: Givinostat (DB12645)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Givinostat 100 mg/d
Trial: 16834644
Drug: Propiverine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propiverine 20 mg once daily
Trial: 7933523
Drug: Biapenem (L-627)
RxNorm normalized name: L
DrugBank: Biapenem (DB13028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biapenem (L-627) administered intravenously at daily doses of 17-37.5 mg/kg for 4-7 consecutive days
Trial: 7933523
Drug: Biapenem (L-627)
RxNorm normalized name: L
DrugBank: Biapenem (DB13028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biapenem (L-627) at a dose of 6 mg/kg
Trial: 7933523
Drug: Biapenem (L-627)
RxNorm normalized name: L
DrugBank: Biapenem (DB13028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biapenem (L-627) at a dose of 12 mg/kg
Trial: 3063133
Drug: Propofol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2 mg/kg bolus, then 0.2 mg/kg/min infusion for 10 min)
Trial: 3063133
Drug: Diazepam (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.3 mg/kg bolus)
Trial: 3063133
Drug: Thiopental (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental (5 mg/kg bolus)
Trial: 31125155
Drug: NTP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTP treatment
Trial: 30073253
Drug: Topical dornase
RxNorm normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical dornase alfa (5 drops each ear twice a day for 7 days)
Trial: 30073253
Drug: Ofloxacin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (5 drops each ear twice a day for 7 days)
Trial: 27007392
Drug: CoQ (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ (200 mg)
Trial: 27007392
Drug: Both supplements
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both supplements (n-3 fatty acids and CoQ)
Trial: 24802626
Drug: Magnet group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnet group (ICD therapy suspended with a magnet)
Trial: 24802626
Drug: Off group
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Off group (ICD therapy programmed off)
Trial: 22374377
Drug: S-Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-Ketamine (0.5 mg/kg i.m. bolus followed by 2 μg/kg/min i.v. continuous infusion for 12 h)
Trial: 18565884
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (RT) with 6 months of combined androgen suppression therapy (AST)
Trial: 18565884
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (RT) with less than 6 months of combined androgen suppression therapy (AST)
Trial: 16043985
Drug: RDP58 100
RxNorm normalized name: RDP58
DrugBank: RDP58 (DB06566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RDP58 100 mg
Trial: 16043985
Drug: RDP58 200
RxNorm normalized name: RDP58
DrugBank: RDP58 (DB06566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RDP58 200 mg
Trial: 16043985
Drug: RDP58 300
RxNorm normalized name: RDP58
DrugBank: RDP58 (DB06566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RDP58 300 mg
Trial: 12502122
Drug: 0.5% fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% fluorouracil topical cream applied once daily for 1, 2, or 4 weeks
Trial: 12502122
Drug: 0.5% fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% fluorouracil topical cream
Trial: 7718459
Drug: Enteric-coated aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated aspirin (300 mg) daily for 4 months
Trial: 7718459
Drug: Placebo (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (one tablet) daily for 4 months
Trial: 2381302
Drug: Dicalcium phosphate
RxNorm normalized name: DICALCIUM PHOSPHATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dicalcium phosphate (129 mmol) and glucose (500 ml/10% sol)
Trial: 30152390
Drug: Oral steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral steroids (prednisolone)
Trial: 23377514
Drug: Clindamycin phosphate
RxNorm normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin phosphate 1.2%/BPO 2.5% gel
Trial: 18098001
Drug: Methamphetamine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methamphetamine treatment approaches
Trial: 15606443
Drug: Trimethoprim 200
RxNorm normalized name: trimethoprim 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim 200 mg given twice daily for 5 days
Trial: 12089223
Drug: 1.0 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/m2 oral topotecan with 1,000 mg GF120918
Trial: 12089223
Drug: 1.0 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/m2 intravenous topotecan with 1,000 mg GF120918
Trial: 12089223
Drug: 1.0 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/m2 oral topotecan without GF120918
Trial: 12089223
Drug: 1.0 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/m2 intravenous topotecan without GF120918
Trial: 9453518
Drug: Tissue-type plasminogen
RxNorm normalized name: Tissue-type plasminogen activator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue-type plasminogen activator with heparin estimated by aPTT
Trial: 7822520
Drug: terbinafine, 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terbinafine, 250 mg/day
Trial: 7822520
Drug: griseofulvin, 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: griseofulvin, 500 mg/day
Trial: 30057104
Drug: High-dose PPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose PPI (40 mg twice-daily)
Trial: 30057104
Drug: Low-dose PPI
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose PPI (20 mg once-daily)
Trial: 30057104
Drug: Aspirin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (300 mg per day in the UK, 325 mg per day in Canada)
Trial: 30057104
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of high-dose PPI and aspirin
Trial: 30057104
Drug: Low-dose PPI
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose PPI without aspirin
Trial: 25759177
Drug: Home-based oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based oral care training programme
Trial: 25759177
Drug: Routine oral
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine oral care education
Trial: 22354743
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D(3) supplementation (20,000 IU weekly)
Trial: 18030230
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1000 mg daily for 12 months)
Trial: 18030230
Drug: Calcium (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1000 mg daily for 12 months) + Vitamin D2 (50,000 IU monthly for 6 months)
Trial: 17373638
Drug: Vildagliptin 100
RxNorm normalized name: vildagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin 100 mg qd
Trial: 12802214
Drug: Pharmaceutical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical treatment for chronic illnesses
Trial: 12802214
Drug: Pharmaceutical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical treatment
Trial: 10778797
Drug: Aquatic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquatic therapy (water) at 30 degrees/s
Trial: 10778797
Drug: Dry land
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dry land therapy at 30 degrees/s
Trial: 10778797
Drug: Aquatic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquatic therapy (water) at 45 degrees/s
Trial: 10778797
Drug: Dry land
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dry land therapy at 45 degrees/s
Trial: 30105847
Drug: Topical liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical liposomal hydroquinone
Trial: 25379688
Drug: Active supplement
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active supplement (500 mg olive leaf extract, 100 mg green coffee bean extract, 150 mg beet powder)
Trial: 22546837
Drug: Docetaxel (T)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel (T) 75 mg/m² on day 1 of a 21-day cycle for six cycles
Trial: 15138163
Drug: Corticosteroids plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids plus daclizumab (1 mg/kg)
Trial: 15138163
Drug: Corticosteroids (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (2 mg/kg)
Trial: 15257932
Drug: Autologous transplantation
RxNorm normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous transplantation or maintenance chemotherapy (given to 84 patients without a sibling donor)
Trial: 15257932
Drug: Autologous transplantation
RxNorm normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous transplantation or maintenance chemotherapy (without donor)
Trial: 10333984
Drug: Befloxatone (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Befloxatone (up to 160 mg single dose or 80 mg/day for 7 days)
Trial: 10333984
Drug: Befloxatone (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Befloxatone (up to 20 mg once daily)
Trial: 10333984
Drug: Befloxatone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Befloxatone (10 mg dose)
Trial: 10333984
Drug: Befloxatone (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Befloxatone (various doses)
Trial: 2654849
Drug: Intravenous theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous theophylline (7.9 +/- 0.4 mg/kg)
Trial: 19148629
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of DHA/EPA (3.0 g/day, t.i.d. for 28 days)
Trial: 19148629
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of DHA/EPA (3.0 g/day, t.i.d. for 28 days)
Trial: 17529899
Drug: Enteric-coated mycophenolate
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteric-coated mycophenolate sodium (EC-MPS) 720 mg twice a day
Trial: 17529899
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 1000 mg twice a day
Trial: 15061265
Drug: Dopaminergic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopaminergic and non-dopaminergic treatment (off-medication)
Trial: 9493577
Drug: 1 l
RxNorm normalized name: BLUE 1 LAKE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 l gelatin‐based plasma substitute (Gelofusine)
Trial: 8043455
Drug: Vinblastine slow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinblastine slow infusion
Trial: 8043455
Drug: Vinblastine bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinblastine bolus injection
Trial: 1818430
Drug: Klion ointment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Klion ointment
Trial: 76857
Drug: Injection/compression sclerotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection/compression sclerotherapy
Trial: 21806517
Drug: Two or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two or four counselling sessions involving cognitive behaviour therapy and motivational interviewing techniques to manage methamphetamine use.
Trial: 18257156
Drug: Antimicrobial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial therapy with sparfloxacine and vibromagnetolaser therapy (VMLG‐10 unit)
Trial: 18257156
Drug: Antimicrobial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial therapy with sparfloxacine and 10 sessions of manual massage
Trial: 18257156
Drug: Vibromagnetolaser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibromagnetolaser therapy (VMLG‐10 unit)
Trial: 11187872
Drug: High-dose FVIII
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose FVIII regimen
Trial: 11187872
Drug: Low-dose FVIII
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose FVIII regimen
Trial: 11187872
Drug: Bypass therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bypass therapy (on demand)
Trial: 29770528
Drug: Control for
RxNorm normalized name: Anti Acne Control Formula Top
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control for age, sex, and medication received
Trial: 24326421
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate (TE; 125 mg/wk) + Finasteride (5 mg/day)
Trial: 24326421
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate (TE; 125 mg/wk)
Trial: 2201266
Drug: Artificial surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial surfactant treatment
Trial: 19152520
Drug: Intralesional injection
RxNorm normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injection of 5-aminolevulinic acid (ALA)
Trial: 19152520
Drug: Conventional photodynamic
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional photodynamic therapy (PDT)
Trial: 16201049
Drug: Domestic fixed-dose
RxNorm normalized name: domestic cow dander extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domestic fixed-dose combinations (rifampicin 120 mg, isoniazid 80 mg, pyrazinamide 250 mg for 2 months; rifampicin 300 mg, isoniazid 150 mg for 4 months)
Trial: 16201049
Drug: Domestic fixed-dose
RxNorm normalized name: domestic cow dander extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domestic fixed-dose combinations
Trial: 11098962
Drug: Midazolam (0.1-0.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.1-0.35 mg/kg/hr)
Trial: 11098962
Drug: 2% Propofol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% Propofol (1.5-6 mg/kg/hr)
Trial: 9031577
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration during a 4-week double-blind and placebo-controlled study with a 2-week single-blind placebo lead-in period.
Trial: 8341050
Drug: Individually focused
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individually focused cognitive behavioral (CB) treatment
Trial: 8341050
Drug: Relationship enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relationship enhancement (RE) of brief cognitive behavioral treatments
Trial: 26038078
Drug: Light buccopalatal
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light buccopalatal jiggling forces (25 g)
Trial: 26038078
Drug: Heavy buccopalatal
RxNorm normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heavy buccopalatal jiggling forces (225 g)
Trial: 26038078
Drug: Continuous buccal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous buccal forces (positive control)
Trial: 12873621
Drug: THC infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC infusion and marijuana smoking
Trial: 10416877
Drug: Progestational drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progestational drugs
Trial: 6962421
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus B.C.G.
Trial: 27741414
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (systemic antibiotics only)
Trial: 26485385
Drug: Local injection
RxNorm normalized name: Sclerosing agents for local injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injection of lidocaine with 1 mg of morphine (MLA group)
Trial: 26485385
Drug: Local injection
RxNorm normalized name: Sclerosing agents for local injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injection of lidocaine alone (LA group)
Trial: 23569029
Drug: 9 mg
RxNorm normalized name: fiber 469 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg Uceris®
Trial: 23569029
Drug: 9 mg
RxNorm normalized name: fiber 469 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg Entocort® EC
Trial: 22156352
Drug: Dark chocolate
RxNorm normalized name: Ensure Original Dark Chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dark chocolate 30 g/day for fifteen days
Trial: 22156352
Drug: White chocolate
RxNorm normalized name: chocolate allergenic extract
DrugBank: Cocoa (DB10977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White chocolate 25 g/day for fifteen days (Control)
Trial: 19827910
Drug: Pioglitazone/metformin fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone/metformin fixed-dose combination (FDC) therapy
Trial: 19827910
Drug: Pioglitazone/metformin FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone/metformin FDC therapy
Trial: 6313376
Drug: Ranitidine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 200 mg daily for 4 weeks
Trial: 6313376
Drug: Ranitidine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 200 mg daily
Trial: 29352654
Drug: Standard Treatment
RxNorm normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard Treatment Control (CON)
Trial: 22577905
Drug: Intrathecal hyperbaric
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal hyperbaric bupivacaine (6, 7, 8, 9, 10, or 11 mg) in obese group (BMI ≥ 27.5 kg/m(2))